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Endoplasmic reticulum aminopeptidase 1 (ERAP1) is an essential component of the immune system,
becauseittrimspeptideprecursorsandgeneratestheN-terminiofthefinalMHCclassI-restrictedepitopes.
To examine ERAP1’s unique properties of length- and sequence-dependent processing of antigen
precursors, we report a 2.3 A ˚ resolution complex structure of the ERAP1 regulatory domain. Our study
reveals a binding conformation of ERAP1 to the carboxyl terminus of a peptide, and thus provides direct
evidence for the molecular ruler mechanism.
A
ntigen processing is an integral part of cell-mediated immune surveillance and responses that involve
MHC-restriction and T cell recognition
1. Processed antigenic peptides, when presented on cell surface
by MHC molecules to T cells, serve as identity tags to be monitored and responded to by our immune
system. To be presented by MHC class I molecules, endogenous antigens need to be cut into 8 to 11 residues in
length in order to fit into the MHC binding groove
2,3. The precursors of class I antigenic peptides are generated
mainly byproteasomes in the cytosol to have the correct C-terminus but with an N-terminal extension of several
aminoacids
4.Thesepeptideprecursorsarethentransportedintothelumenoftheendoplasmicreticulum(ER)by
transporter associated with antigen processing (TAP), that is an MHC-encoded peptide transporter capable of
importing both mature epitopes and N-extended precursors ranging in length from 7 to more than 20 amino
acids
5–7. TAP transports the longer precursors more efficiently than the mature epitopes
8. Thus, many peptide
precursors need to be further trimmed inside the ER to generate the final N-termini of mature epitopes
9,10.
ERAP1 (ER aminopeptidase 1), also named ERAAP (ER aminopeptidase associated with antigen processing),
isoneoftwoERluminalaminopeptidasesthatmakethefinalN-terminaltrimmingofclassIantigenicpeptides
11–13.
A second enzyme is called ERAP2 or L-RAP (leukocyte-derived arginine aminopeptidase)
14. These two
enzymes are highly homologous and both are induced by interferon-c, a potent stimulator of MHC class I
presentation. ERAP1 is identical to a previously isolated enzyme called adipocyte-derived leucine aminopepti-
dase
15, whose immunological relevance was not previously recognized. As expected for a peptidase involved in
generating MHC class I antigens, ERAP1 is expressed in most cells
16, and its expression level is strongly upre-
gulated by interferon-c
11–13. ERAP1 strongly prefers peptide substrates that are 9–16 residues in length
12,13,17,18,
which corresponds to the lengths of peptides transported selectively by TAP
5–8. The length preference allows
ERAP1 to rapidly trim N-extended peptides to 8–9 residues, but further cleavages occur much more slowly or
cease completely
12,13,17,18, producing the optimal length of epitopes that are presented by most MHC class I
molecules. Moreover, ERAP1 catalysis is activated by an unusual allosteric mechanism, termed the ‘‘molecular
ruler’’mechanismthatmonitorsthe substratelength and the identity ofthe C-terminal amino acids9–16 residues
away from the N-terminal cleavage site
18. Thus, the substrate specificity of ERAP1 influences which peptides are
trimmed and available for MHC class I presentation and is critical for immunological function.
To gain insights into the molecular ruler mechanism, our group has been pursuing the structure-function
studiesoftheERAP1enzyme.Duringthepreparationofthismanuscript,twostructuresofERAP1werereported
by other groups
19,20. However, without a peptide bound in those ERAP1 structures, and with relative low resolu-
tions(2.7–3A ˚),theERAP1mechanismofpeptidelength-andsequence-dependentactivityremainedelusive.We
report here a 2.3 A ˚-resolution structure of the ERAP1 regulatory domain in complex with a peptide fragment.
ThiscomplexstructureallowsadirectvisualizationofpeptidebindingtotheERAP1regulatorydomain,andthus
provides a structural basis for the molecular ruler mechanism.
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ERAP1 C-terminal domain proposed as the putative regulatory
domain.Thereisindication thatERAP1hasamodularorganization
for its molecular ruler mechanism: binding of peptide’s C-terminus
to a regulatory site, distinct from the catalytic site, allosterically
activates its peptidase activity
18. Insights into the structure of the
ERAP1 regulatory domain should elucidate its unusual length
dependence and substrate specificity, as well as the mechanism of
antigen processing. Based on sequence comparisons, we hypothe-
sized that the unique C-terminal half of ERAP1 contains the C-
terminus binding groove for antigenic peptide precursors and acts
astheregulatorydomainforthemolecularrulermechanism.ERAP1
is a zinc-containing metallopeptidase that is a member the ‘‘M1/
gluzincin’’ family of peptidases
15,21. It is most closely related to two
other aminopeptidases of the M1 family: ERAP2 and P-LAP
22, with
43–49% sequence identity spread along the entire sequences. There
was also evidence to suggest that ERAP2 trims peptides in a way
similar to ERAP1
17. These three enzymes recognize and cleave
peptide precursors, and belong to the oxytocinase subfamily of the
M1 peptidases
21. However, sequence alignment with other members
of the M1 family that have a broader range of substrates shows that
homologyisonlyclustered withinthe N-terminalhalfofERAP1: the
M1 homology region. In contrast, there is no significant sequence
homology between the C-terminal half of ERAP1 and other broad-
substrate-range M1 members. Nonetheless, this C-terminal domain
ishighlyconservedamongthethreeoxytocinasesubfamilymembers
that all bind and trim peptide substrates
14,21, and thus is highly likely
to harbor the regulatory site to sense and recognize peptide’s length
and sequences near its C-terminus.
StructureofERAP1C-terminaldomainincomplexwithapeptide
C-terminus.Wehavedetermineda2.3A ˚ resolutioncrystalstructure
of the ERAP1 regulatory domain (a.a. 529–941) in complex with a
peptidecarboxyl-terminus,withRcryst50.19andRfree50.26.Other
crystallographicdatacollectionandrefinementstatisticsaresumma-
rized in Table 1. This ERAP1 regulatory domain is composed of two
subdomains:asmallbeta-sandwichwithtwob-sheets(residues530–
611),andalargerbowl-shapedalpha-helix domainwith16a-helices
(residues 614–941) forming a concave surface (Fig. 1). The overall
structure is similar to the corresponding domain of the full-length
ERAP1structure intheclosedform
20,withrootmeansquare(r.m.s.)
deviations of 1.7 A ˚ for all main-chain atoms; main differences result
fromaslighthingemovementbetweenthesetwosubdomains.Inthe
crystal, the C-terminus end of a peptide, an engineered His-tag tail
fromaneighboringmolecule(-RMHHHHHH-CO2),isdockinginto
a groove on the concave surface of the alpha-helix domain. Inter-
actionsbetweenERAP1andthepeptidemainlyinvolvehydrophobic
and van der Waals contacts, plus a few hydrogen-bond interactions
with the carboxylate end of the peptide (Fig. 1b, and see below). As
oriented in Fig. 1a, this peptide C-terminus binding groove is facing
towardstheN-terminalcatalyticsiteinanintactERAP1proteinwith
a large internal cavity in-between the N-terminal catalytic zinc site
and the C-terminal regulatory domains
19,20. The location of the C-
terminus binding groove, ,29 A ˚ from the N-terminal catalytic zinc
site (Zn in Fig. 1a), is consistent with the expectation for a C-
terminus anchoring site of a molecular ruler to monitor the length
and sequence of an antigen precursor of nine- to ten-residue in
length. Longer antigenic precursors could be accommodated by
bulging or zig-zagging in the middle of peptide into the central
and widest portion (,30 A ˚) of the large substrate cavity.
Allosterical activation of the ERAP1 aminopeptidase activity by
histidine-containing peptides. ERAP1 is likely to bind and process
His-containing antigen precursors since histidine is an anchor or
preferred residue at various positions of antigen ligands for many
MHC class I molecules. Histidine had been reported to be an anchor
residueattheP2positionofantigenpeptidesforHLA-B*3801,atthe
P2 position for HLA-B*39011, and at the P7 (PC-2, the 2
nd position
N-terminal to the peptide carboxyl-terminal) position for mouse
H Qa-2
23. It is also a preferred residue at various positions of anti-
gens, including the P9/PC carboxyl-terminal position of antigen
peptides for HLA-B*2705, or the P8/PC-1 position for HLA-B8,
HLA-B*3701, HLA-Cw*0401, or the P7/PC-2 position for HLA-
A*3101, HLA-B8, HLA-B*3902
23. In addition, HLA-A3 had also
been shown to bind peptides with a histidine at the PC position
24.
ThusbindingoftheHis-tagpeptidetotheERAP1regulatorydomain
as observed in the crystal structure is likely to reflect a functional
conformation of ERAP1’s substrate recognition.
Table 1 | Crystallographic data collection and refinement statistics
ERAP1 Regulatory Domain in complex with a peptide
Data collection
Space Group P21
Cell Dimensions:
a, b, c (A ˚) 63.8, 67.3, 65.9
a, b, c (
o) 90.0, 110.2, 90.0
Resolution (A ˚)
a 53.2–2.3 (2.4–2.3)
I/sigma-I 8.2 (2.3)
Completeness (%) 99.5 (99.7)
Rsym (%)
b 15 (69)
Structure refinement
Resolution (A ˚) 53.2–2.3
No. of reflections 22,138
Rcryst/Rfree 0.19/0.26
R.m.s.deviations
Bond-lengths (A ˚) 0.05
Bond-angles (u) 2.1
Ramachandran plot
Most favored regions (%) 97.3
Additional allowed regions (%) 2.2
B-factors (A ˚ 2)
Protein 21.7
Water 24.7
aNumbers in parenthesis refer to the outermost resolution bin.
bRsym 5 ShklSi |Ihkli2ÆIhkliæ |/ShklSiÆIhkliæ.
Figure 1 | Structure of the ERAP1 C-terminal regulatory domain in
complex with a peptide. (a) Overall structure of the ERAP1 regulatory
domain, with respect to the N-terminal catalytic domain. The b-sandwich
and a-helix subdomains of the regulatory domain are shown as a ribbon
diagram and colored in blue and green, respectively. Bound peptide is
shownasastickmodelandcoloredbyatomtypes.Locationofthecatalytic
zinc site in the N-terminal domain is shown as a grey sphere, with its
distance to the peptide C-terminus indicated in angstroms. (b) ERAP1
interactions with bound His-tag peptide (sequence MHHHHHH-CO2).
Bound peptide is shown as a thick stick model and colored by atom types:
green for main-chain carbons, yellow for side-chain carbons, blue for
nitrogens, and red for oxygens. Side-chains of selected residues of ERAP1
arealsoshownandlabeledasathinstickmodelingray.Dottedlinesdenote
hydrogen-bond interactions.
www.nature.com/scientificreports
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reported for the substrate sequence preference of ERAP1. For exam-
ple, Arg, Lys and His at the PC position were reported by Chang
et al.
18 to be suboptimal substrates, yet Evnouchidou et al. concluded
thatArgandLysarethebestanchorresiduesatthePCposition
25.To
verify the functional relevance of the His-tag binding, we performed
enzyme activation assays. It has been shown that peptides shorter
than 8 residues are not long enough to be efficiently trimmed by
ERAP1
19. However, these short peptides can bind to the regulatory
domain of ERAP1 and allosterically activate the hydrolysis of L-
AMC(leucine-7-amido-4-methyl-coumarin)bytheERAP1catalytic
site. To demonstrate a functional binding of His-tag peptides, we
monitored activation of L-AMC hydrolysis by a series of peptides
based on the bound His-tag sequence RMHHHHHH. Consistent
withpreviousstudies
19,25,ERAP1hydrolyzesL-AMCwithalowbasal
level in the absence of peptide (open bar in Fig. 2), or in the presen-
ce of a predominantly negatively charged peptide (the peptide
EEEEGEG); such a negatively charged peptide was considered to
be a poor substrate for ERAP1
25. We then examined activation of
L-AMC hydrolysis by peptides containing C-terminal sequences of
twonaturallyprocessedantigenicpeptidesthathaveahistidineatthe
PCposition
26:TRYPILAGH(acytochromeP450epitope,underlined
C-terminal fragment used in Fig. 2), and RRIKEIVKKH (a HSP 86
epitope). In the presence of these two C-terminal fragments of anti-
genic peptides, a significant increase of ERAP1 aminopeptidase
activity on L-AMC over the basal level was detected, suggesting an
allosterical binding to the regulatory domain. Similarly, a significant
increase of ERAP1 aminopeptidase activity was also detected in the
presence of the His-tag peptides MHHHHHH and RMHHHHHH.
Activation was further increased by placing an arginine anchor near
the C-terminus of the peptide MHHHRHH, which is consistent
with ERAP1 specificity studies at this (PC-2) peptide position
25
(see below). Altogether, these His-containing peptides can thus bind
to the ERAP1 regulatory domain to allosterically activate the ami-
nopeptidaseactivityattheERAP1’scatalyticzincsite.SincemanyT-
cells reactive to self and prevalent antigens presented by MHC are
eliminated during their development in the thymus to avoid auto-
immunity
27, small but significant effect from minor antigens, similar
to those observed in Figure 2, could play critical roles for protection
against foreign pathogens.
Molecular modeling of an optimal binding peptide into the
ERAP1 regulatory site. To analyze the peptide binding groove
and potential pockets or sub-sites for recognizing substrate side-
chains and C terminus, we modeled an Arg-Ala-Phe sequence into
the last three positions (PC-2, PC-1, and PC) of the bound His-tag
peptide (Fig. 3a). This tri-peptide model sequence was based on
substrate specificity of ERAP1 at PC-2 and PC positions
25; in the
crystal the PC-1 side chain points away from the binding groove and
Figure 2 | Allosteric activation of ERAP1 by His-tag peptides. Activation
of L-AMC hydrolysis by a series of peptides with a histidine at the PC
position. As negative controls, hydrolysis activities were measured in the
absenceofapeptide,orwithanegativelychargedpeptide(EEEEGEG)that
wasconsideredtobeapoorsubstrateforERAP1
25.PeptidesYPILAGHand
KEIVKKH are derived from two naturally processed antigenic peptides, a
cytochrome P450 epitope and a HSP 86 epitope, respectively. The other
three peptides, MHHHHHH, RMHHHHHH, and MHHHRHH, are
derived from the bound C-terminal His-tag determined in the crystal
structure. The basal activity in which L-AMC hydrolysis was measured in
the absence of added peptide is indicated by the open bar and the
horizontal line. Standard deviations of three separate experiments are
indicated by error bars.
Figure 3 | SpecificitypocketsofERAP1forpeptide’sanchors. (a)Overlayofamodeledtri-residuepeptide(yellow)ontothecrystalstructure ofthelast
threepositionsofthebound His-tagpeptide(green).Themodeltri-residue peptideArg-Ala-Phewasbuiltbasedonthelastthree positions(PC-2,PC-1,
PC carboxyl-terminal) of the bound His-tag peptide, with minor adjustments for better fit (see text and Methods). Surrounding side-chains of ERAP1
residues are shown and labeled. (b) The C terminus binding groove of ERAP1 is shown as solvent accessible surfaces colored by electrostatic potentials:
fromredtobluefornegativelychargedtopositivelychargedareas.Themodeltri-peptideisshownasathickstickmodelcoloredbyatomtypes:greenfor
main-chain carbons, yellow for side-chain carbons, blue for nitrogens, and red for oxygens. Side-chains of selected ERAP1 residues are also shown and
labeled in white. (c) Schematic outlines of specificity pockets, with surrounding side-chains of selected ERAP1 residues shown and labeled.
www.nature.com/scientificreports
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into the binding groove and sub-pockets, small adjustments were
made (Fig. 3a): ,0.9 A ˚ towards Glu831, and a side-chain rotation
to allow an aromatic ring interaction between the PC Phe and
Phe803. One pocket contains predominantly non-polar atoms
located at the floor of the peptide binding cleft, surrounded by Ile
681, Leu733, Leu734, Val 737, and Leu769, with Phe803 ready to
make an aromatic ring interaction with the PC phenylalanine side-
chain of the model peptide (Figs. 3a&b). Another deep pocket is
located in close proximity to the PC-2 arginine side-chain, with
the entry wrapped around by residues Leu769, Phe803, and
Ser799, and tunnels into the negatively charged residues Glu802
and Glu831. This E802/E831 pocket appears to be ideal for
binding to an anchoring side-chain of arginine or lysine of
antigenic precursors. As shown in Fig. 2, adding an arginine
anchor in the PC-2 position of the peptide substantially increases
the peptide’s activation capacity. Meanwhile, the carboxylate end
of the peptide ligand makes direct or water-mediated contacts
with Tyr684, Lys685, Arg807, and Arg841, and is partially exposed
to bulk solvents. Model building suggests that small adjustments
could be made to allow extensions (e.g. with an amine or glycine)
from the current C-terminus location, similar to the C-terminal
extension of an MHC class I binding mode
28. Most of the residues
made up of the two binding pockets for peptide side-chain
anchors are polymorphic among ERAP1, ERAP2, and P-LAP
22,
suggesting different binding specificities for these three enzymes.
On the other hand, several residues in and around the carboxylate
binding site are conserved among these oxytocinase subfamily
members. These conserved residues, which include Tyr684 and
Arg841, provide additional contacts to recognize a constant feature
of antigenic precursors. In the crystal structure, Tyr684 make a
water-mediated contact with the peptide carboxylate end whereas
Arg841 makes a direct contact with the main-chain carbonyl of the
PC-2 residue(Fig. 1c)and a water-mediated contact with the peptide
carboxylate end.
Discussion
The high resolution structure of ERAP1/peptide complex provides
detailed insights into the peptide C-terminus recognition and the
molecular ruler mechanism. Structural comparisons between the
open and closed conformations of ERAP1 suggest that a confor-
mational change with reorientation of a key catalytic residue is
involved in the molecular ruler mechanism
19,20. Adding the new
peptide binding conformation reported here, we propose a
detailed model for the ERAP1’s molecular ruler mechanism to
sense the substrate length and recognize the sequence near the
peptide C-terminal end (Fig. 4). In the absence of a peptide
anchored at the regulatory pocket, ERAP1 stays in the lower-
activity open conformation, resulting in the basal level of L-
AMC hydrolysis (Fig. 4a). This lower-activity open conformation
could also account for some low level trimming of peptides down
to 4 or 5 residues
4, by cutting peptide’s N-terminus without hav-
ing its C-terminus in contact with the regulatory pocket. In the
presence of a peptide ligand longer than 9 or 10 residues, ERAP1
uses specificity pockets at its regulatory domain to anchor the
peptide’s side-chains at or near the carboxyl-terminus (Fig. 4b).
This anchoring and recognition triggers conformational changes
to activate the N-terminal catalytic center located ,30 A ˚ away. As
observed in Figure 2, short peptides can also bind to the regula-
tory domain of ERAP1 and activate in trans the hydrolysis of L-
AMC by the N-terminal catalytic site. Nonetheless, for a peptide
precursor to be efficiently processed, it needs to be 9 or 10 resi-
dues long to be able to simultaneously place its N- and C-terminal
ends into the catalytic zinc site and the C-terminus docking pock-
ets, respectively. Longer peptides could be accommodated by bul-
ging or zig-zagging into the widest portion of the large substrate
cavity. Thus, even though the architects of the binding grooves are
different, ERAP1 and MHC class I molecules utilize the same
strategies to bind a large repertoire of antigenic peptides, by bind-
ing at both N- and C-termini of peptides with common feature
and side-chain anchors, but allowing flexibility in sequence and
length through bulging or zig-zagging in the middle
2,3.I ti si n t e r -
esting to note that ERAP1 has dual specificities at the PC position
of a peptide nonamer series: preferring either a positively charged
(R, K) or a hydrophobic side-chain (F, V, M)
25.T h i si sl i k e l yt o
result from different specificity pockets involved in anchoring
these two types of peptide anchors. As for the model peptide
(Fig. 3b), the Phe803 pocket could bind a phenylalanine anchor.
However, for a peptide precursor with an arginine at the PC
position, it is plausible to insert this positively charged side-chain
anchor into the Glu802/Glu831 pocket instead. For the latter
group of peptides with a PC arginine, additional affinity could
come from the conserved Arg841 to make direct contacts with
the peptide’s carboxylate end.
Figure 4 | Proposed model for the molecular ruler mechanism. (a) A small substrate (L-AMC shown) cannot concurrently reach the catalytic site and
the regulatory pockets. ERAP1 stays in the lower-activity open conformation and inefficiently hydrolyses L-AMC. This could also account for some low
leveltrimmingofpeptidesdownto4or5residues
4.(b)Apeptidelongerthan9or10residuescanreachthecatalyticzincsitefromtheregulatorydomain
binding groove where its carboxyl-terminus is anchored. Triggered by the peptide anchoring into the regulatory pockets (lightening), ERAP1 changes
intothehigher-activityclosedconformationandefficientlytrimsoneresiduefromthepeptide’sN-terminalend.Slightlyshorterandlongerpeptidestake
theless(red)andmore(green)bulgingpaths,respectively.AllostericactivationofERAP1onL-AMChydrolysisbyashortpeptidecanalsobeachievedin
trans (a pair of red slashes) by concurrently occupying the catalytic site and regulatory pockets.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 1 : 186 | DOI: 10.1038/srep00186 4Methods
Protein expression and purification. Baculovirus cDNA encoding for human
ERAP1 full-length protein or C-terminal domain was constructed with a C-terminal
hexa-histidine tag according to the protocols of the manufacturer (Invitrogen). The
presence of ERAP1 protein and the integrity of the purified recombinant bacmid
DNA were verified by PCR. To express the protein, the bacmid DNA was transfected
into Sf9 insect cells according to the manufacturer’s protocols. The protein was
expressed and harvested 48 hours after infection by adding the P4 recombinant viral
stockintoSf9insectcellswithanMOIof1 pfu/cell.Proteinexpressionwasconfirmed
by western blot using primary antibody against the hexa-histidine tag.
Cell pellets were re-suspended in 50 mM NaH2PO4, pH 8.0, 300 mM NaCl and
10 mM imidazole, and lysed by freeze-thaw cycles and sonication. The supernatant
was loaded onto a Ni-NTA column and washed several times with 50 mM sodium
phosphate buffer, pH 8.0, containing 300 mM NaCl, and 10–30 mM imidazole. The
protein was then eluted with 50 mM sodium phosphate buffer, pH 8.0, containing
300 mMNaCl,and400 mMimidazole.Glycerolwasaddedtotheelutedsolutiontoa
final concentration of 16% (v/v), and then the concentrated protein was further
purified through a Superdex 200 gel filtration column (Amersham Pharmacia) by
FPLC system with a buffer containing 10 mM Tris, pH 7.5, 10 mM NaCl. A single
peak for ERAP1 enzyme or C-terminal domain was collected and the protein was
concentrated to 3–7 mg/ml for crystallization.
Enzyme Activation Assays. Aminopeptidase activity was determined by measuring
the fluorescence of 7-amido-4-methylcoumarin (AMC) released by hydrolysis of
Leucine-AMC (L-AMC). Assays were performed at 25uC in 200 mlo f5 0m M
Tris/HCl, pH 8.0, 0.1 M NaCl, containing 0.75 mgm l
21 ERAP1 enzyme in the
presence or absence of 100 mM peptides. Hydrolysis of 50 mM Leucine-AMC (L-
AMC) was followed for 5 minutes and measured using an excitation wavelength of
380 nm and an emission wavelength of 460 nm. Fluorescence intensities were
calibrated using AMC as standard
12.
Crystallization, data collection and structure determination. Initial crystallization
screening at room temperature used the hanging-drop vapor diffusion technique.
Promising conditions were further refined at 4uC. To improve the crystal quality,
micro-seeding method was used for final crystallization. The best looking crystal was
formed above a well solution containing 100 mM Tris, pH 8.5 and 8% PEG8000 at
4uC in 4 days.
For data collection, the crystal was cryoprotected in solution containing 100 mM
Tris-HCl buffer (pH 8.0) and 30% glycerol. X-ray data were collected using the
beamline X29 at National Synchrotron Light Source (NSLS). The data was processed
with the Mosflm
29 and the CCP4 suite
30.
The structure of ERAP1 C-terminal domain was determined by molecular
replacement method using the ERAP1 intact protein structure (PDB code 2XDT)
20
as the starting model, with residues 530–610 deleted and all remaining residues
changed to alanines to reduce model bias. Molecular replacement was preformed
with Molrep and refinements were performed with the Refmac program. 5% of
the total reflection data was excluded from the refinement cycles and used to
calculate the free Rfactor (Rfree) for monitoring refinement progress. Rigid body and
subsequent restrained refinements and model building with COOT
31 led to the final
crystallographic Rwork/Rfree of 19.1%/26.1% at 2.3 A ˚ resolution. The X-ray data and
structure refinement statistics are shown in Table 1. A structural alignment of
the ERAP1 C-terminal domain with corresponding domain of Tricon Interacting
Factor F3 (TIFF3)
32 is shown in Supplementary Figure 1. All the figures were
drawn using PyMOL (DeLano Scientific) and labels were added using AdobeH
Photoshop.
Modeling of the tri-residue peptide Arg-Ala-Phe. The modeled tri-residue peptide
Arg-Ala-Phe is based on the last three positions (PC-2, PC-1, and PC) of the
experimentally determined His-tag peptide. These three histidine residues were first
mutatedtoArg,Ala,andPhe,respectively.Sidechainsofthemutatedtripeptide were
then adjusted to avoid steric clashes with the ERAP1 structure, using the torsion
option in Coot
31. Additional adjustments were made to better fit into the binding
grooveandsub-pockets:,0.9A ˚ towardsGlu831,andaside-chainrotationofPCPhe
to allow an aromatic ring interaction between the PC Phe and Phe803 (Fig. 3a). The
modeled tripeptide in complex with ERAP1 domain was further refined with energy
minimization protocol with 20 steps of Steepest Descent algorithm in GROMOS96
force field using the SwissPdb Viewer program
33.
Accession code. Diffraction data and coordinates are deposited under accession
code 3RJO in the Protein Data Bank.
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